Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TMPRSS4 | Q9NRS4 | 8/20 | 0.67 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.60 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.57 |
| ▸ | TSHR | P16473 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.57 |
| ▸ | MEN1 | O00255 | 4/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.53 |
| ▸ | P2RX1 | P51575 | 3/20 | 0.53 |
| ▸ | P2RX4 | Q99571 | 3/20 | 0.53 |
| ▸ | P2RX7 | Q99572 | 3/20 | 0.53 |
| ▸ | IKBKB | O14920 | 1/20 | 0.53 |
| ▸ | CHUK | O15111 | 1/20 | 0.53 |
| ▸ | KDR | P35968 | 1/20 | 0.53 |
| ▸ | FLT3 | P36888 | 1/20 | 0.53 |
| ▸ | MYLK | Q15746 | 1/20 | 0.53 |
| ▸ | MAP4K5 | Q9Y4K4 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 2/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30771730 | 0.90 | TMPRSS4 (0.63) | TMPRSS4TRPV1TSHRSMN1; SMN2MEN1 | |
| SCHEMBL331420 | 0.90 | TMPRSS4 (0.63) | TMPRSS4TRPV1TSHRSMN1; SMN2MEN1 | |
| SCHEMBL330023 | 0.87 | TMPRSS4 (0.83) | TMPRSS4TRPV1CHRNA7TSHRSMN1; SMN2 | |
| SCHEMBL29367614 | 0.86 | TMPRSS4 (0.73) | TMPRSS4MEN1KMT2AP2RX1P2RX4 | |
| SCHEMBL331595 | 0.86 | TMPRSS4 (0.73) | TMPRSS4MEN1KMT2AP2RX1P2RX4 | |
| SCHEMBL330554 | 0.85 | TMPRSS4 (0.67) | TMPRSS4TRPV1CHRNA7TSHRSMN1; SMN2 | |
| SCHEMBL2700887 | 0.83 | TRPV1 (0.76) | TMPRSS4TRPV1CHRNA7TSHRSMN1; SMN2 | |
| SCHEMBL330643 | 0.82 | TMPRSS4 (0.69) | TMPRSS4TRPV1CHRNA7TSHRSMN1; SMN2 | |
| SCHEMBL330396 | 0.82 | TMPRSS4 (0.59) | TMPRSS4SMN1; SMN2MEN1KMT2AP2RX1 | |
| SCHEMBL3497252 | 0.82 | TRPV1 (0.57) | TMPRSS4TRPV1CHRNA7TSHRSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8263657-B2 | Blocking neurokinins; using a benzene compound containing hydroxy or acetoxy group; antiinflammatory agents | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2012-09-11 | — | — | US | claimed |
| US-12503425-B2 | Methods of treating or controlling cytotoxic cerebral edema | AEROMICS, INC. (US) | 2025-12-23 | — | — | US | disclosed |
| US-20240360077-A1 | METHODS | AEROMICS, INC. | 2024-10-31 | — | — | US | disclosed |
| US-11873266-B2 | Methods of treating or controlling cytotoxic cerebral edema consequent to an ischemic stroke | AEROMICS, INC. (US) | 2024-01-16 | — | — | US | disclosed |
| US-20220081391-A1 | METHODS | AEROMICS, INC. | 2022-03-17 | — | — | US | disclosed |
| CN-109512805-B | Compounds for the treatment of aquaporin mediated diseases | 埃罗米克斯公司 | 2021-12-31 | — | — | CN | disclosed |
| US-11084778-B2 | Methods of treating cardiac edema, neuromyelitis optica, and hyponatremia | AEROMICS, INC. (US) | 2021-08-10 | — | — | US | disclosed |
| US-20180334424-A1 | METHODS | AEROMICS, INC. | 2018-11-22 | — | — | US | disclosed |
| EP-2846787-B1 | Compounds for use in the treatment of aquaporin-mediated diseases | AEROMICS INC (US) | 2018-08-29 | — | — | EP | disclosed |
| US-9994514-B2 | Methods of treating cerebral edema and spinal cord edema | AEROMICS, INC. (US) | 2018-06-12 | — | — | US | disclosed |
| CN-100370975-C | Inflammatory cytokine production dissociation inhibitor | INST OF MEDICINE MOLECULAR DES (JP) | 2008-02-27 | — | — | CN | disclosed |
| CN-101125138-A | Inhibitors against the production and release of inflammatory cytokines | INST MED MOLECULAR DESIGN INC (JP) | 2008-02-20 | — | — | CN | disclosed |
| EP-1847263-A2 | Inhibitors against the production and release of inflammatory cytokines | Institute of Medicinal Molecular Design, Inc. (JP) | 2007-10-24 | — | — | EP | disclosed |
| EP-1844766-A2 | Inhibitors against the production and release of inflammatory cytokines | Institute of Medicinal Molecular Design, Inc. (JP) | 2007-10-17 | — | — | EP | disclosed |
| US-20060094718-A1 | 2-Morpholinocarbonyloxy-),5-(phenylethenyl,N-((3,5-bistrifluoromethyl-)phenyl)-benzamide; inhibitors of nuclear factor kappa B activation; cytokine suppressive antiinflammatory drugs(interleukin (IL-1, IL-6, IL-8) inhibitors); tumor necrosis factor (TNF-alpha) inhibitors; side effects reduction | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2006-05-04 | — | — | US | disclosed |
| CN-1658855-A | O-substituted hydroxyaryl derivatives | INST MED MOLECULAR DESIGN INC (JP) | 2005-08-24 | — | — | CN | disclosed |
| EP-1512397-A1 | O-SUBSTITUTED HYDROXYARYL DERIVATIVES | Institute of Medicinal Molecular Design, Inc. (JP) | 2005-03-09 | — | — | EP | disclosed |
| US-20040259877-A1 | Inhibitors against the production and release of inflammatory cytokines | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2004-12-23 | — | — | US | disclosed |
| CN-1489458-A | Inflammatory cytokine production dissociation inhibitor | ��ʽ����ҽҩ��������о��� | 2004-04-14 | — | — | CN | disclosed |
| EP-1352650-A1 | INHIBITORS AGAINST THE PRODUCTION AND RELEASE OF INFLAMMATORY CYTOKINES | Institute of Medicinal Molecular Design, Inc. (JP) | 2003-10-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180334424-A1 | METHODS | AQP4, AQP1, AQP3 | TMPRSS4 1257/4885TRPV1 1299/4885CHRNA7 4199/4885 |
| US-12503425-B2 | Methods of treating or controlling cytotoxic cerebral edema | AQP4, AQP1, AQP3 | TMPRSS4 1043/4885TRPV1 904/4885CHRNA7 4091/4885 |
| US-20220081391-A1 | METHODS | AQP4, AQP1, AQP3 | TMPRSS4 1257/4885TRPV1 1299/4885CHRNA7 4199/4885 |
| US-20060094718-A1 | 2-Morpholinocarbonyloxy-),5-(phenylethenyl,N-((3,5-bistrifluoromethyl-)phenyl)-benzamide; inhibitors of nuclear factor kappa B activation; cytokine suppressive antiinflammatory drugs(interleukin (IL-1, IL-6, IL-8) inhibitors); tumor necrosis factor (TNF-alpha) inhibitors; side effects reduction | IL1A, TNF, NFKBIA | TMPRSS4 4278/4885TRPV1 1623/4885CHRNA7 2997/4885 |
| US-11084778-B2 | Methods of treating cardiac edema, neuromyelitis optica, and hyponatremia | AQP4, AQP1, AQP3 | TMPRSS4 946/4885TRPV1 1102/4885CHRNA7 4190/4885 |
| US-11873266-B2 | Methods of treating or controlling cytotoxic cerebral edema consequent to an ischemic stroke | AQP4, AQP1, AQP3 | TMPRSS4 1444/4885TRPV1 1156/4885CHRNA7 4283/4885 |
| US-20040259877-A1 | Inhibitors against the production and release of inflammatory cytokines | NFKBIA, IL1B, IKBKB | TMPRSS4 3292/4885TRPV1 1398/4885CHRNA7 2622/4885 |
| US-20240360077-A1 | METHODS | AQP4, AQP1, AQP3 | TMPRSS4 1415/4885TRPV1 1464/4885CHRNA7 4105/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.